

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	16.5	78.9	(42.0-135.0)	Male	12	10.6	112.9	(58.3-197.3)
Female	5	6.2	80.9	(26.1-188.9)	Female	13	8.8	147.8	(78.6-252.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.3	215.1	(86.2-443.2)	Male	3	2.6	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	9.0	110.5	(52.9-203.3)
Female	64	61.7	103.7	(79.8-132.4)	Female	8	8.1	98.5	(42.4-194.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	8	6.6	120.5	(51.9-237.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	23.5	85.2	(52.0-131.6)	Female	9	6.4	140.1	(63.9-266.0)
Female	34	22.4	151.5	(104.9-211.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	5.0	nc	(nc-nc)
Male	6	4.4	136.5	(49.8-297.1)	Female	5	5.3	93.9	(30.3-219.2)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	52	63.8	81.5	(60.9-106.9)
Male	4	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	3.8	183.0	(73.3-377.1)
<u>Kidney & Renal Pelvis</u>					Female	1	2.4	nc	(nc-nc)
Male	6	8.0	74.7	(27.3-162.6)	<u>Testis</u>				
Female	7	5.0	140.8	(56.4-290.1)	Male	3	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	9	8.7	103.5	(47.2-196.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.6	89.6	(28.9-209.2)	Female	12	13.7	87.3	(45.0-152.5)
Female	3	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	220	224.1	98.2	(85.6-112.0)
Male	5	4.0	126.2	(40.7-294.5)	Female	232	214.9	107.9	(94.5-122.8)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	30.7	120.6	(84.9-166.2)					
Female	32	29.9	107.0	(73.2-151.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	16.5	72.7	(37.5-127.0)	Male	22	12.2	180.6	(113.2-273.5)
Female	5	5.9	85.1	(27.4-198.7)	Female	13	10.3	126.4	(67.2-216.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	10.2	68.8	(27.6-141.7)
Female	94	72.3	129.9	(105.0-159.0)	Female	11	8.3	133.3	(66.4-238.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.5	nc	(nc-nc)	Male	4	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	25.0	96.1	(61.5-143.0)	Female	13	7.2	180.1	(95.8-308.0)
Female	15	21.5	69.7	(39.0-115.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	5.3	188.9	(90.4-347.4)
Male	2	4.8	nc	(nc-nc)	Female	5	5.0	99.4	(32.0-232.1)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	69.7	88.9	(68.2-114.0)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.3	nc	(nc-nc)
Male	5	9.3	54.0	(17.4-126.0)	<u>Testis</u>				
Female	4	5.3	nc	(nc-nc)	Male	8	3.2	250.4	(107.8-493.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	12	11.3	105.9	(54.6-184.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.1	115.0	(46.1-236.9)	Female	11	15.9	69.3	(34.6-124.0)
Female	5	4.6	108.8	(35.1-253.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	215	243.9	88.2	(76.8-100.8)
Male	6	4.7	128.6	(47.0-279.9)	Female	233	232.5	100.2	(87.8-113.9)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	31.9	43.9	(24.0-73.6)					
Female	24	29.3	81.9	(52.4-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.7	78.4	(37.5-144.2)	Male	4	7.9	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	2	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	74.0	(23.8-172.6)
Female	41	44.3	92.6	(66.4-125.6)	Female	2	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	18.0	100.2	(59.3-158.3)	Female	3	4.6	nc	(nc-nc)
Female	18	15.9	113.4	(67.2-179.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.9	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	52	48.9	106.3	(79.4-139.5)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	2.9	205.1	(74.9-446.4)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	7	6.1	115.2	(46.1-237.3)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	6.0	83.8	(27.0-195.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.1	nc	(nc-nc)	Female	7	10.0	70.3	(28.1-144.8)
Female	3	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	171	170.5	100.3	(85.8-116.5)
Male	5	3.0	166.0	(53.5-387.5)	Female	121	153.4	78.9	(65.5-94.3)
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	23.9	121.3	(81.2-174.2)					
Female	19	21.9	86.7	(52.2-135.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	12.6	142.5	(84.4-225.2)	Male	0	7.1	nc	(nc-nc)
Female	5	5.0	99.5	(32.1-232.2)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
Female	41	42.1	97.4	(69.9-132.1)	Female	7	6.2	112.4	(45.0-231.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	17.1	128.6	(80.6-194.7)	Female	7	4.5	154.3	(61.8-318.0)
Female	26	18.3	141.7	(92.5-207.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.7	134.2	(43.2-313.2)
Male	4	3.1	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	44.5	139.4	(106.9-178.7)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.0	nc	(nc-nc)
Male	8	5.5	146.2	(63.0-288.1)	<u>Testis</u>				
Female	6	3.7	162.8	(59.4-354.4)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.9	129.5	(41.7-302.3)	Female	10	9.4	106.4	(50.9-195.7)
Female	4	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	173	158.4	109.2	(93.5-126.7)
Male	3	2.7	nc	(nc-nc)	Female	167	156.9	106.5	(90.9-123.9)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	23.1	82.3	(49.5-128.5)					
Female	37	23.6	157.1	(110.6-216.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	34.9	97.5	(67.5-136.3)	Male	13	21.2	61.4	(32.7-105.0)
Female	9	14.5	62.0	(28.3-117.6)	Female	15	18.2	82.4	(46.1-135.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.2	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	9	5.6	160.0	(73.0-303.8)	Female	5	4.6	108.2	(34.9-252.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	14	18.2	76.8	(42.0-128.9)
Female	147	130.7	112.5	(95.0-132.2)	Female	23	18.4	124.7	(79.0-187.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	10	13.0	76.9	(36.8-141.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	48.8	108.6	(81.4-142.1)	Female	17	13.9	122.2	(71.2-195.7)
Female	56	54.3	103.2	(78.0-134.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.5	114.4	(59.0-199.8)
Male	3	8.9	nc	(nc-nc)	Female	15	12.7	117.7	(65.8-194.1)
Female	6	2.8	211.0	(77.0-459.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	126.6	94.0	(77.8-112.5)
Male	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.1	nc	(nc-nc)	Male	8	8.1	99.3	(42.7-195.6)
<u>Kidney & Renal Pelvis</u>					Female	3	6.1	nc	(nc-nc)
Male	19	16.0	118.6	(71.3-185.1)	<u>Testis</u>				
Female	13	10.9	119.7	(63.7-204.7)	Male	1	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	5.5	145.6	(62.7-286.9)	Male	5	5.2	96.4	(31.1-224.9)
Female	2	1.6	nc	(nc-nc)	Female	19	16.3	116.3	(70.0-181.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11.2	98.1	(48.9-175.6)	Female	31	28.9	107.2	(72.8-152.2)
Female	8	10.0	80.3	(34.6-158.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	424	453.7	93.4	(84.8-102.8)
Male	6	7.9	75.7	(27.6-164.7)	Female	506	473.5	106.9	(97.7-116.6)
Female	3	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	61	63.5	96.0	(73.4-123.3)					
Female	76	67.1	113.3	(89.2-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	6	2.0	294.2	(107.4-640.4)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	2.9	205.6	(75.1-447.5)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	9.6	114.6	(57.1-205.0)
Male	0	0.2	nc	(nc-nc)	Female	9	6.7	133.7	(61.0-253.7)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.3	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.8	75.8	(39.1-132.4)	Male	15	10.4	143.8	(80.4-237.1)
Female	6	6.3	95.4	(34.8-207.6)	Female	11	9.1	120.9	(60.3-216.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.2	154.2	(49.7-359.9)	Male	2	2.5	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	8.9	158.1	(86.3-265.2)
Female	50	63.1	79.3	(58.8-104.5)	Female	13	8.2	157.7	(83.9-269.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.9	nc	(nc-nc)	Male	12	6.4	186.7	(96.4-326.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	22.7	66.2	(37.0-109.2)	Female	2	6.6	nc	(nc-nc)
Female	18	23.1	77.9	(46.1-123.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.8	103.1	(33.2-240.6)
Male	5	4.2	118.3	(38.1-276.1)	Female	8	5.4	146.9	(63.3-289.5)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	60.8	83.9	(62.4-110.3)
Male	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.5	nc	(nc-nc)
Male	8	7.9	101.9	(43.9-200.7)	<u>Testis</u>				
Female	3	5.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	9.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.4	91.8	(29.6-214.2)	Female	17	13.8	123.2	(71.7-197.2)
Female	5	4.6	109.3	(35.2-255.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	208	216.4	96.1	(83.5-110.1)
Male	5	3.8	129.9	(41.9-303.1)	Female	196	219.5	89.3	(77.2-102.7)
Female	2	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	29.5	91.4	(60.2-132.9)					
Female	33	29.9	110.4	(76.0-155.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	17.6	28.4	(9.1-66.2)	Male	12	12.3	97.6	(50.4-170.4)
Female	8	7.3	110.2	(47.5-217.2)	Female	11	12.7	86.4	(43.1-154.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	Female	5	2.3	217.8	(70.2-508.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.8	110.7	(57.1-193.3)
Female	92	72.8	126.4	(101.9-155.1)	Female	12	10.2	118.0	(60.9-206.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.6	nc	(nc-nc)	Male	6	7.4	81.0	(29.6-176.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	25.2	87.4	(54.7-132.3)	Female	9	8.3	108.6	(49.6-206.2)
Female	23	26.8	85.9	(54.4-128.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.4	93.1	(30.0-217.4)
Male	7	4.6	150.6	(60.3-310.4)	Female	1	6.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	82	66.8	122.7	(97.6-152.3)
Male	2	3.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	3.7	nc	(nc-nc)	Male	5	4.1	121.2	(39.0-282.8)
<u>Kidney & Renal Pelvis</u>					Female	1	2.9	nc	(nc-nc)
Male	6	8.5	70.7	(25.8-153.9)	<u>Testis</u>				
Female	4	5.8	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	9	13.8	65.4	(29.9-124.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.3	123.3	(56.3-234.0)	Female	19	16.2	117.1	(70.5-182.9)
Female	1	5.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	214	250.5	85.4	(74.4-97.7)
Male	2	4.3	nc	(nc-nc)	Female	240	265.8	90.3	(79.2-102.5)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	32.3	37.1	(19.2-64.8)					
Female	17	34.1	49.8	(29.0-79.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	33.3	108.1	(75.7-149.7)	Male	20	21.9	91.3	(55.8-141.1)
Female	10	12.8	78.1	(37.4-143.7)	Female	28	18.5	151.6	(100.7-219.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.8	162.4	(81.0-290.6)	Male	7	5.4	129.4	(51.8-266.5)
Female	6	5.7	104.4	(38.1-227.2)	Female	5	4.1	121.6	(39.2-283.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	20	18.6	107.5	(65.6-166.0)
Female	120	133.9	89.6	(74.3-107.2)	Female	17	17.0	100.3	(58.4-160.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.8	nc	(nc-nc)	Male	14	14.2	98.4	(53.7-165.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	48.3	89.1	(64.4-120.0)	Female	8	13.8	58.1	(25.0-114.6)
Female	36	47.3	76.2	(53.3-105.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	10.4	135.0	(73.7-226.5)
Male	10	9.2	108.9	(52.1-200.3)	Female	12	11.1	107.9	(55.7-188.6)
Female	3	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	175	133.0	131.6	(112.8-152.6)
Male	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.2	nc	(nc-nc)	Male	9	7.7	116.4	(53.1-220.9)
<u>Kidney & Renal Pelvis</u>					Female	4	5.1	nc	(nc-nc)
Male	9	16.9	53.4	(24.4-101.4)	<u>Testis</u>				
Female	14	10.4	134.1	(73.2-225.0)	Male	4	4.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.7	nc	(nc-nc)	Male	8	5.8	138.8	(59.8-273.5)
Female	1	1.6	nc	(nc-nc)	Female	26	18.3	141.9	(92.7-208.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	11.3	106.0	(54.7-185.2)	Female	29	29.6	97.9	(65.6-140.6)
Female	7	9.2	75.8	(30.4-156.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	491	461.7	106.3	(97.1-116.2)
Male	7	8.5	82.6	(33.1-170.1)	Female	397	455.1	87.2	(78.9-96.2)
Female	1	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	62.9	74.7	(54.9-99.4)					
Female	36	61.5	58.5	(41.0-81.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	1.1	438.7	(141.4-1023.8)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	4.0	276.1	(137.6-494.0)
Male	0	0.1	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	61	50.0	121.9	(93.3-156.6)	Male	34	30.4	111.8	(77.4-156.2)
Female	20	21.4	93.4	(57.0-144.2)	Female	25	27.6	90.6	(58.6-133.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.9	101.1	(46.1-191.9)	Male	8	7.7	103.5	(44.6-204.0)
Female	5	8.4	59.8	(19.3-139.4)	Female	10	6.8	147.7	(70.7-271.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	27	26.0	103.9	(68.5-151.2)
Female	205	195.7	104.8	(90.9-120.1)	Female	24	27.2	88.2	(56.5-131.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	8.3	nc	(nc-nc)	Male	10	18.1	55.2	(26.4-101.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	67	69.3	96.6	(74.9-122.7)	Female	21	20.6	101.8	(63.0-155.7)
Female	83	78.1	106.2	(84.6-131.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	14.9	107.1	(61.2-173.9)
Male	10	12.7	78.7	(37.7-144.7)	Female	20	18.6	107.8	(65.8-166.5)
Female	3	4.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	164	182.9	89.7	(76.5-104.5)
Male	3	3.8	nc	(nc-nc)	<u>Stomach</u>				
Female	7	3.3	215.2	(86.2-443.4)	Male	8	11.5	69.6	(30.0-137.2)
<u>Kidney & Renal Pelvis</u>					Female	9	8.6	104.3	(47.6-198.1)
Male	23	23.0	100.2	(63.5-150.3)	<u>Testis</u>				
Female	11	16.4	67.2	(33.5-120.3)	Male	8	6.8	117.7	(50.7-231.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	7.9	152.6	(78.8-266.6)	Male	12	7.6	158.1	(81.6-276.2)
Female	5	2.4	207.6	(66.9-484.5)	Female	28	25.6	109.3	(72.6-157.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	15.9	94.1	(52.6-155.3)	Female	37	43.4	85.3	(60.1-117.6)
Female	14	14.6	96.2	(52.6-161.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	618	651.6	94.8	(87.5-102.6)
Male	9	11.1	80.8	(36.9-153.3)	Female	681	704.3	96.7	(89.6-104.2)
Female	5	4.5	110.1	(35.5-256.9)					
<u>Lung and Bronchus</u>									
Male	68	92.2	73.7	(57.2-93.5)					
Female	72	101.5	70.9	(55.5-89.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	15	19.4	77.5	(43.4-127.9)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.3	81.9	(29.9-178.2)	Female	1	1.9	nc	(nc-nc)
Female	7	5.8	121.2	(48.6-249.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	18	20.3	88.8	(52.6-140.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.7	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Male	59	71.3	82.8	(63.0-106.8)
Female	0	0.2	nc	(nc-nc)	Female	67	62.6	107.0	(83.0-135.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.2	nc	(nc-nc)	Male	59	71.3	82.8	(63.0-106.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	67	62.6	107.0	(83.0-135.9)
Female	2	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	6	9.4	63.9	(23.3-139.1)	Male	59	71.3	82.8	(63.0-106.8)
Female	9	8.0	112.4	(51.3-213.4)	Female	67	62.6	107.0	(83.0-135.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.5	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	7	10.1	69.3	(27.8-142.9)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	3.7	268.6	(128.6-493.9)	Female	0	1.0	nc	(nc-nc)
Female	5	3.2	154.2	(49.7-359.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	10	10.4	95.7	(45.8-176.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	36.5	87.8	(60.0-123.9)
Female	0	0.1	nc	(nc-nc)	Female	33	33.4	98.7	(67.9-138.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	4.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.8	76.6	(28.0-166.8)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	8.2	97.6	(42.0-192.2)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	23	29.0	79.3	(50.2-118.9)
Male	0	0.5	nc	(nc-nc)	Female	17	25.2	67.4	(39.2-107.9)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	3.9	127.1	(40.9-296.5)					
Female	1	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	13.7	160.6	(100.6-243.2)	Male	15	9.6	157.0	(87.8-258.9)
Female	6	4.8	125.4	(45.8-272.9)	Female	8	8.1	98.9	(42.6-195.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.0	165.1	(53.2-385.2)	Male	4	2.3	nc	(nc-nc)
Female	6	2.5	243.2	(88.8-529.3)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.0	74.9	(27.4-163.1)
Female	66	56.3	117.3	(90.7-149.3)	Female	12	6.6	182.1	(94.0-318.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	6	6.0	99.2	(36.2-215.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	20.1	99.4	(60.7-153.5)	Female	7	5.6	124.0	(49.7-255.5)
Female	19	17.1	111.3	(67.0-173.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.3	140.0	(51.1-304.7)
Male	1	3.8	nc	(nc-nc)	Female	8	4.1	197.2	(84.9-388.6)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	55.4	126.3	(98.5-159.6)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.1	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	3	7.3	nc	(nc-nc)	<u>Testis</u>				
Female	2	4.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.4	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	11	8.8	124.6	(62.1-222.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.8	124.5	(45.5-271.0)	Female	8	12.4	64.3	(27.7-126.7)
Female	3	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	211	195.0	108.2	(94.1-123.9)
Male	4	3.6	nc	(nc-nc)	Female	206	184.0	112.0	(97.2-128.3)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	26.3	64.7	(37.6-103.5)					
Female	29	24.2	119.6	(80.1-171.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	14.4	152.3	(95.4-230.5)	Male	7	8.5	82.2	(32.9-169.4)
Female	7	5.7	123.7	(49.5-254.8)	Female	7	6.9	100.9	(40.4-207.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
Female	40	49.5	80.9	(57.8-110.1)	Female	7	7.1	97.9	(39.2-201.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	5.1	98.7	(31.8-230.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	19.9	115.7	(73.3-173.7)	Female	8	5.3	151.0	(65.0-297.5)
Female	23	21.0	109.4	(69.3-164.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.3	116.8	(37.7-272.7)
Male	4	3.6	nc	(nc-nc)	Female	6	5.0	120.9	(44.2-263.2)
Female	2	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	50.5	97.1	(71.8-128.4)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.4	nc	(nc-nc)
Male	3	6.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	6.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.6	129.2	(47.2-281.3)	Female	10	10.8	92.3	(44.2-169.7)
Female	6	3.9	154.0	(56.2-335.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	181	183.4	98.7	(84.8-114.1)
Male	2	3.1	nc	(nc-nc)	Female	173	181.8	95.2	(81.5-110.4)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	25.9	119.5	(81.2-169.6)					
Female	35	26.1	133.9	(93.2-186.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	41.0	109.6	(80.0-146.7)	Male	23	26.9	85.6	(54.2-128.4)
Female	12	16.8	71.3	(36.8-124.5)	Female	25	23.7	105.3	(68.1-155.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.4	107.3	(49.0-203.8)	Male	3	6.5	nc	(nc-nc)
Female	9	7.4	122.2	(55.8-232.0)	Female	5	5.3	93.8	(30.2-218.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	20	22.9	87.4	(53.4-135.1)
Female	159	162.0	98.1	(83.5-114.6)	Female	19	22.0	86.4	(52.0-135.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	7.5	nc	(nc-nc)	Male	20	16.3	122.5	(74.8-189.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	58.3	111.4	(86.0-142.0)	Female	22	17.0	129.3	(81.0-195.8)
Female	60	61.8	97.0	(74.0-124.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	12.5	72.0	(32.8-136.6)
Male	16	10.9	147.1	(84.0-239.0)	Female	13	14.6	89.2	(47.5-152.6)
Female	1	3.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	133	156.3	85.1	(71.2-100.8)
Male	3	4.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	3.2	nc	(nc-nc)	Male	9	9.5	94.5	(43.1-179.4)
<u>Kidney & Renal Pelvis</u>					Female	6	6.9	87.6	(32.0-190.6)
Male	22	20.1	109.4	(68.6-165.7)	<u>Testis</u>				
Female	10	13.2	75.7	(36.3-139.3)	Male	5	7.2	69.0	(22.2-161.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	6.8	nc	(nc-nc)	Male	7	7.3	96.4	(38.6-198.7)
Female	1	1.9	nc	(nc-nc)	Female	21	23.4	89.8	(55.6-137.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	14.1	113.3	(64.7-184.0)	Female	31	35.7	86.9	(59.1-123.4)
Female	12	12.2	98.6	(50.9-172.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	542	558.5	97.1	(89.1-105.6)
Male	12	9.8	123.0	(63.5-214.9)	Female	533	575.6	92.6	(84.9-100.8)
Female	4	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	88	76.5	115.0	(92.2-141.6)					
Female	84	79.7	105.4	(84.1-130.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	22.2	103.4	(65.6-155.2)	Male	8	13.0	61.3	(26.4-120.9)
Female	7	8.3	83.8	(33.6-172.7)	Female	7	10.5	66.9	(26.8-137.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	133.1	(42.9-310.7)	Male	4	3.4	nc	(nc-nc)
Female	8	3.3	246.1	(106.0-485.0)	Female	0	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	11.3	62.2	(24.9-128.1)
Female	55	76.4	72.0	(54.2-93.7)	Female	7	10.6	66.1	(26.5-136.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	5	8.0	62.8	(20.2-146.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	30.7	127.1	(90.4-173.8)	Female	9	8.1	111.6	(50.9-211.8)
Female	28	30.4	92.0	(61.1-133.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	6.6	nc	(nc-nc)
Male	9	5.6	159.5	(72.8-302.9)	Female	9	7.2	124.4	(56.8-236.1)
Female	3	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	81.2	97.3	(77.0-121.3)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.3	nc	(nc-nc)
Male	7	10.0	69.9	(28.0-144.1)	<u>Testis</u>				
Female	7	6.4	109.5	(43.9-225.6)	Male	6	2.4	254.0	(92.8-552.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	10	9.5	105.4	(50.5-193.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	6.9	nc	(nc-nc)	Female	23	17.1	134.2	(85.1-201.4)
Female	4	5.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	267	286.3	93.3	(82.4-105.1)
Male	6	4.9	122.7	(44.8-267.0)	Female	267	273.9	97.5	(86.1-109.9)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	40.9	68.5	(45.5-99.0)					
Female	64	39.7	161.2	(124.1-205.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.8	nc	(nc-nc)	Male	5	3.4	146.4	(47.2-341.7)
Female	0	2.1	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	8	20.1	39.7	(17.1-78.3)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.0	113.2	(51.6-214.9)	Female	0	2.1	nc	(nc-nc)
Female	10	7.5	134.1	(64.2-246.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	15	21.7	69.1	(38.6-114.0)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.6	nc	(nc-nc)	Female	7	4.6	152.1	(60.9-313.5)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	Male	72	75.3	95.7	(74.8-120.5)
Female	0	0.3	nc	(nc-nc)	Female	68	71.0	95.8	(74.4-121.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.4	nc	(nc-nc)	Male	72	75.3	95.7	(74.8-120.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	68	71.0	95.8	(74.4-121.4)
Female	2	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	11	10.8	102.2	(51.0-183.0)	Male	72	75.3	95.7	(74.8-120.5)
Female	15	10.6	141.3	(79.0-233.1)	Female	68	71.0	95.8	(74.4-121.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	6.4	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	21	26.2	80.3	(49.7-122.7)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.2	109.3	(52.3-200.9)	Female	4	2.8	nc	(nc-nc)
Female	12	10.5	114.2	(58.9-199.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.0	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	24.6	101.7	(65.8-150.1)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	3.8	132.9	(42.8-310.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	7	5.7	123.1	(49.3-253.7)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	88.3	96.3	(76.9-119.0)
Male	1	1.5	nc	(nc-nc)	Female	93	94.7	98.2	(79.2-120.3)
Female	2	0.6	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	20	12.1	165.7	(101.1-255.9)	<u>Bladder, Urinary</u>				
Female	12	13.1	91.7	(47.3-160.2)	Male	3	6.4	nc	(nc-nc)
					Female	3	2.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	74.9	116.2	(93.0-143.3)	Male	48	41.6	115.5	(85.1-153.1)
Female	22	26.1	84.4	(52.8-127.7)	Female	48	31.5	152.6	(112.5-202.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.7	102.6	(53.0-179.3)	Male	13	11.2	116.2	(61.8-198.7)
Female	14	9.8	142.7	(78.0-239.5)	Female	10	8.2	121.6	(58.2-223.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.3	nc	(nc-nc)	Male	44	36.3	121.3	(88.2-162.9)
Female	256	230.8	110.9	(97.7-125.3)	Female	20	32.5	61.5	(37.5-94.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	9.0	133.3	(68.8-232.9)	Male	26	24.4	106.7	(69.7-156.4)
Female	17	11.9	142.7	(83.1-228.4)	Female	17	11.9	142.7	(83.1-228.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	91	100.9	90.2	(72.6-110.8)	Female	25	24.5	102.2	(66.1-150.8)
Female	101	93.6	107.9	(87.8-131.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	21.9	105.0	(66.5-157.5)
Male	15	18.2	82.6	(46.2-136.3)	Female	34	22.5	151.1	(104.6-211.1)
Female	3	5.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	373	258.5	144.3	(130.0-159.7)
Male	4	4.6	nc	(nc-nc)	<u>Stomach</u>				
Female	5	3.7	135.9	(43.8-317.1)	Male	14	17.0	82.4	(45.0-138.3)
<u>Kidney & Renal Pelvis</u>					Female	11	10.2	107.6	(53.6-192.5)
Male	37	31.7	116.8	(82.2-161.0)	<u>Testis</u>				
Female	19	19.7	96.3	(58.0-150.5)	Male	8	7.0	114.8	(49.4-226.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	11.1	54.2	(19.8-117.9)	Male	2	9.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	14	27.9	50.1	(27.4-84.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	22.7	119.0	(78.4-173.1)	Female	43	51.8	82.9	(60.0-111.7)
Female	27	17.2	157.1	(103.5-228.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1049	927.2	113.1	(106.4-120.2)
Male	13	15.4	84.6	(45.0-144.7)	Female	891	837.7	106.4	(99.5-113.6)
Female	7	5.4	128.4	(51.5-264.7)					
<u>Lung and Bronchus</u>									
Male	122	135.3	90.2	(74.9-107.6)					
Female	121	125.0	96.8	(80.3-115.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	17	19.4	87.4	(50.9-140.0)	Female	4	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	3	7.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.7	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	20.2	54.4	(27.1-97.3)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.9	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	53	73.7	72.0	(53.9-94.1)
Male	0	1.3	nc	(nc-nc)	Female	54	67.9	79.5	(59.7-103.7)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	10.2	127.8	(68.0-218.5)					
Female	11	9.4	117.3	(58.5-209.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	7.1	84.9	(31.0-184.8)	Female	3	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.4	nc	(nc-nc)	Male	33	32.4	101.9	(70.1-143.1)
Female	1	0.1	nc	(nc-nc)	Female	27	23.5	114.9	(75.7-167.2)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	4.5	265.1	(136.8-463.0)
Female	0	0.4	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	4.5	265.1	(136.8-463.0)
Female	0	0.1	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.8	81.7	(47.5-130.8)	Male	20	11.7	171.0	(104.4-264.1)
Female	4	6.0	nc	(nc-nc)	Female	9	7.6	118.3	(54.0-224.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	9	10.2	88.6	(40.4-168.3)
Female	72	56.0	128.7	(100.7-162.0)	Female	2	7.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	6	7.0	86.3	(31.5-187.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	28.2	88.5	(57.3-130.7)	Female	10	5.9	170.7	(81.7-313.9)
Female	15	21.8	68.8	(38.5-113.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	6.1	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	Female	5	5.2	96.8	(31.2-226.0)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	72.8	75.5	(56.9-98.3)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.4	nc	(nc-nc)
Male	9	9.0	100.2	(45.7-190.1)	<u>Testis</u>				
Female	4	4.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	6	7.0	85.9	(31.4-186.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.3	126.5	(54.5-249.3)	Female	12	12.6	95.4	(49.3-166.7)
Female	2	4.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	219	259.7	84.3	(73.5-96.3)
Male	1	4.3	nc	(nc-nc)	Female	187	198.1	94.4	(81.3-108.9)
Female	3	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	37.7	71.6	(47.2-104.2)					
Female	25	28.2	88.6	(57.3-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	11.5	113.4	(60.3-193.9)	Male	5	8.0	62.3	(20.1-145.5)
Female	5	4.0	125.5	(40.5-293.0)	Female	12	6.9	173.8	(89.7-303.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	53	46.7	113.4	(84.9-148.3)	Female	4	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	7	5.1	138.5	(55.5-285.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	16.9	136.2	(86.3-204.4)	Female	6	4.7	127.2	(46.5-276.9)
Female	11	14.5	75.7	(37.8-135.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.6	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	Female	6	3.4	175.5	(64.1-382.1)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	44.5	92.1	(66.1-124.9)
Male	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	<u>Testis</u>				
Female	6	3.5	170.8	(62.4-371.7)	Male	3	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	7.6	79.3	(29.0-172.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.1	nc	(nc-nc)	Female	12	10.2	118.1	(60.9-206.3)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	138	161.4	85.5	(71.8-101.0)
Male	0	3.0	nc	(nc-nc)	Female	161	153.9	104.6	(89.1-122.1)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	21.5	60.4	(32.1-103.4)					
Female	23	19.9	115.8	(73.4-173.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.7	94.9	(50.5-162.4)	Male	5	9.6	52.2	(16.8-121.9)
Female	8	4.9	164.3	(70.8-323.8)	Female	9	8.0	113.1	(51.6-214.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	5	2.5	203.3	(65.5-474.3)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.0	74.7	(27.3-162.6)
Female	57	55.5	102.7	(77.8-133.1)	Female	7	6.6	105.5	(42.3-217.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	5	6.1	81.5	(26.3-190.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	20.1	94.4	(56.8-147.5)	Female	5	5.6	89.1	(28.7-207.8)
Female	14	17.2	81.5	(44.5-136.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.3	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	63	57.3	110.0	(84.5-140.8)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	3.2	156.7	(50.5-365.7)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	8	7.3	109.4	(47.1-215.6)	<u>Testis</u>				
Female	9	4.3	210.8	(96.2-400.1)	Male	3	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.4	245.0	(89.5-533.4)	Male	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	8.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	4.9	144.2	(57.8-297.1)	Female	14	12.5	112.1	(61.2-188.1)
Female	3	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	210	197.4	106.4	(92.5-121.8)
Male	3	3.6	nc	(nc-nc)	Female	208	183.7	113.2	(98.4-129.7)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	26.5	169.8	(123.9-227.3)					
Female	40	24.7	161.8	(115.5-220.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	30.7	58.6	(34.7-92.6)	Male	24	18.2	132.1	(84.6-196.5)
Female	3	11.8	nc	(nc-nc)	Female	27	15.2	177.2	(116.7-257.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	94.8	(30.5-221.2)	Male	1	4.7	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	18	15.7	115.0	(68.1-181.7)
Female	124	110.0	112.7	(93.7-134.4)	Female	16	15.1	106.1	(60.6-172.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.6	nc	(nc-nc)	Male	6	11.0	54.7	(20.0-119.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	42.4	99.1	(71.4-134.0)	Female	15	11.6	129.9	(72.6-214.2)
Female	45	43.4	103.7	(75.7-138.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	9.2	nc	(nc-nc)
Male	1	7.7	nc	(nc-nc)	Female	21	10.2	205.0	(126.9-313.4)
Female	2	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	107	110.8	96.6	(79.2-116.7)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	4.8	nc	(nc-nc)
Male	10	13.8	72.6	(34.8-133.6)	<u>Testis</u>				
Female	5	9.1	55.2	(17.8-128.8)	Male	7	3.4	205.7	(82.4-423.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.8	nc	(nc-nc)	Male	8	4.3	185.6	(79.9-365.8)
Female	0	1.3	nc	(nc-nc)	Female	21	14.1	148.4	(91.8-226.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	9.7	92.8	(42.4-176.3)	Female	19	24.3	78.1	(47.0-122.0)
Female	10	8.1	123.8	(59.3-227.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	329	394.3	83.4	(74.7-93.0)
Male	2	6.7	nc	(nc-nc)	Female	395	391.5	100.9	(91.2-111.4)
Female	1	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	56.0	57.2	(39.1-80.7)					
Female	38	55.5	68.5	(48.5-94.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.1	146.7	(53.6-319.3)	Male	2	3.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	16	17.7	90.3	(51.6-146.7)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.3	95.3	(34.8-207.5)	Female	1	1.8	nc	(nc-nc)
Female	4	5.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.3	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	17.7	113.2	(69.1-174.8)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.5	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	7	3.3	214.7	(86.0-442.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	61	62.7	97.3	(74.4-124.9)
Male	1	1.2	nc	(nc-nc)	Female	63	56.9	110.8	(85.1-141.7)
Female	1	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.0	87.5	(35.1-180.3)					
Female	5	6.8	73.1	(23.6-170.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	11	10.5	104.9	(52.3-187.7)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	6	3.4	175.0	(63.9-381.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	11.7	127.8	(71.5-210.8)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	5.4	nc	(nc-nc)	Male	39	39.8	97.9	(69.6-133.8)
Female	7	4.8	145.8	(58.4-300.4)	Female	38	35.0	108.5	(76.8-149.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.0	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	8	10.1	78.9	(34.0-155.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	4.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	10	11.4	87.5	(41.9-160.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	7	2.3	306.8	(122.9-632.2)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	5.6	nc	(nc-nc)	Male	37	39.5	93.6	(65.9-129.1)
Female	2	4.9	nc	(nc-nc)	Female	31	35.0	88.5	(60.1-125.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	45.6	107.5	(79.6-142.2)	Male	23	27.9	82.4	(52.2-123.7)
Female	23	18.9	121.7	(77.2-182.7)	Female	29	24.2	119.6	(80.1-171.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	8.3	132.2	(65.9-236.5)	Male	2	7.1	nc	(nc-nc)
Female	9	7.6	119.2	(54.4-226.3)	Female	4	6.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	20	24.0	83.5	(51.0-128.9)
Female	149	170.6	87.3	(73.9-102.5)	Female	25	24.1	103.9	(67.2-153.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	7.1	nc	(nc-nc)	Male	21	16.9	124.1	(76.8-189.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	63.6	73.9	(54.3-98.2)	Female	27	18.2	148.5	(97.8-216.1)
Female	63	70.3	89.7	(68.9-114.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	13.7	51.2	(20.5-105.5)
Male	10	11.7	85.8	(41.1-157.8)	Female	9	16.5	54.4	(24.8-103.4)
Female	3	3.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	166	166.5	99.7	(85.1-116.1)
Male	1	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.1	nc	(nc-nc)	Male	3	10.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	7.9	nc	(nc-nc)
Male	26	21.1	123.4	(80.6-180.8)	<u>Testis</u>				
Female	22	14.2	155.0	(97.1-234.7)	Male	8	6.1	130.7	(56.3-257.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	7.2	125.3	(57.2-237.8)	Male	5	7.0	71.6	(23.1-167.1)
Female	4	2.1	nc	(nc-nc)	Female	21	22.3	94.2	(58.3-144.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	14.9	94.3	(51.5-158.1)	Female	44	37.4	117.7	(85.5-158.1)
Female	12	13.2	91.2	(47.1-159.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	564	596.2	94.6	(86.9-102.7)
Male	6	10.4	57.8	(21.1-125.8)	Female	629	619.1	101.6	(93.8-109.9)
Female	4	4.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	89	83.6	106.4	(85.5-131.0)					
Female	106	87.5	121.2	(99.2-146.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	32.2	93.2	(62.9-133.0)	Male	25	23.7	105.6	(68.3-155.9)
Female	16	11.6	137.7	(78.6-223.6)	Female	13	19.4	67.0	(35.6-114.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.7	130.2	(62.3-239.4)	Male	4	5.5	nc	(nc-nc)
Female	7	6.0	117.1	(46.9-241.3)	Female	5	3.8	133.3	(42.9-311.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	20	19.8	101.2	(61.8-156.3)
Female	127	135.2	94.0	(78.3-111.8)	Female	13	16.1	81.0	(43.1-138.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.5	nc	(nc-nc)	Male	20	15.5	129.1	(78.8-199.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	48.3	97.3	(71.5-129.4)	Female	18	13.7	131.6	(77.9-208.0)
Female	36	41.5	86.7	(60.7-120.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	10.4	86.9	(39.7-165.1)
Male	12	9.5	126.4	(65.2-220.8)	Female	5	9.8	50.9	(16.4-118.7)
Female	2	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	143	140.0	102.1	(86.1-120.3)
Male	4	3.7	nc	(nc-nc)	<u>Stomach</u>				
Female	5	2.7	186.9	(60.2-436.2)	Male	6	7.5	79.6	(29.1-173.3)
<u>Kidney & Renal Pelvis</u>					Female	0	4.4	nc	(nc-nc)
Male	27	18.0	150.3	(99.0-218.7)	<u>Testis</u>				
Female	7	10.3	68.3	(27.4-140.7)	Male	8	6.9	116.4	(50.1-229.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.0	83.2	(26.8-194.1)	Male	7	7.0	100.0	(40.1-206.1)
Female	3	1.6	nc	(nc-nc)	Female	21	20.9	100.5	(62.2-153.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	11.9	151.8	(89.9-239.9)	Female	34	30.8	110.5	(76.5-154.5)
Female	11	8.7	125.9	(62.8-225.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	534	480.1	111.2	(102.0-121.1)
Male	6	9.0	67.0	(24.5-145.8)	Female	466	444.8	104.8	(95.5-114.7)
Female	5	2.6	193.3	(62.3-451.1)					
<u>Lung and Bronchus</u>									
Male	88	62.9	140.0	(112.3-172.4)					
Female	75	58.6	128.1	(100.7-160.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.6	131.1	(62.7-241.1)	Male	4	5.3	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	23	30.5	75.3	(47.7-113.0)	Female	8	3.8	208.4	(89.7-410.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	11.1	81.0	(37.0-153.9)	Female	2	3.1	nc	(nc-nc)
Female	11	10.2	107.8	(53.8-193.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	32	29.7	107.9	(73.8-152.4)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	6	3.9	152.4	(55.6-331.6)	Male	0	1.8	nc	(nc-nc)
Female	6	2.4	250.9	(91.6-546.1)	Female	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	2.7	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	8	4.7	168.7	(72.6-332.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.9	nc	(nc-nc)	Female	9	6.7	134.1	(61.2-254.7)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	22	14.3	153.7	(96.3-232.7)	Male	103	106.8	96.5	(78.7-117.0)
Female	19	14.1	135.2	(81.3-211.1)	Female	114	103.8	109.8	(90.6-131.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	9	4.7	190.4	(86.9-361.5)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	5.4	165.2	(75.4-313.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.5	nc	(nc-nc)	Male	14	18.6	75.4	(41.2-126.5)
Female	3	1.9	nc	(nc-nc)	Female	27	15.1	179.2	(118.1-260.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	16	14.6	109.7	(62.6-178.1)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.1	98.1	(31.6-228.9)	Female	3	1.4	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.0	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	10	14.9	67.1	(32.1-123.3)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.0	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	6.4	93.6	(34.2-203.8)	Female	45	50.8	88.6	(64.6-118.6)
Female	3	5.3	nc	(nc-nc)	Female	42	44.8	93.8	(67.6-126.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	369	454.2	81.2	(73.2-90.0)	Male	267	303.8	87.9	(77.7-99.1)
Female	151	188.4	80.2	(67.9-94.0)	Female	267	288.7	92.5	(81.7-104.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	75	97.0	77.3	(60.8-96.9)	Male	88	71.9	122.4	(98.2-150.8)
Female	75	88.4	84.9	(66.8-106.4)	Female	80	59.2	135.1	(107.1-168.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	17	14.4	117.7	(68.5-188.4)	Male	293	258.6	113.3	(100.7-127.1)
Female	1788	1836.0	97.4	(92.9-102.0)	Female	215	250.0	86.0	(74.9-98.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	120	91.2	131.6	(109.1-157.4)	Male	210	178.0	118.0	(102.6-135.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	701	643.7	108.9	(101.0-117.3)	Female	194	195.1	99.4	(85.9-114.5)
Female	750	683.9	109.7	(102.0-117.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	134	137.2	97.7	(81.8-115.7)
Male	107	118.4	90.4	(74.1-109.2)	Female	164	161.7	101.4	(86.5-118.2)
Female	43	36.4	118.2	(85.5-159.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1886	1691.7	111.5	(106.5-116.6)
Male	48	54.7	87.7	(64.7-116.3)	<u>Stomach</u>				
Female	57	48.2	118.2	(89.5-153.1)	Male	136	106.0	128.4	(107.7-151.8)
<u>Kidney & Renal Pelvis</u>					Female	118	75.4	156.5	(129.6-187.5)
Male	234	220.3	106.2	(93.0-120.7)	<u>Testis</u>				
Female	169	150.0	112.7	(96.3-131.0)	Male	81	104.7	77.4	(61.5-96.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	83	73.5	113.0	(90.0-140.0)	Male	94	85.8	109.5	(88.5-134.0)
Female	22	22.0	99.8	(62.5-151.2)	Female	367	297.3	123.4	(111.1-136.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	157	162.8	96.5	(82.0-112.8)	Female	396	405.2	97.7	(88.3-107.8)
Female	137	139.8	98.0	(82.3-115.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6719	6195.6	108.4	(105.9-111.1)
Male	206	106.7	193.0	(167.6-221.3)	Female	6740	6574.0	102.5	(100.1-105.0)
Female	49	40.9	119.8	(88.6-158.4)					
<u>Lung and Bronchus</u>									
Male	981	839.0	116.9	(109.7-124.5)					
Female	908	900.7	100.8	(94.4-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	25.8	89.1	(56.5-133.7)	Male	26	14.8	175.3	(114.5-256.8)
Female	17	9.3	183.2	(106.7-293.3)	Female	11	11.5	95.4	(47.6-170.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	8	3.9	205.1	(88.3-404.1)
Female	6	3.6	166.2	(60.7-361.8)	Female	5	2.9	171.2	(55.2-399.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	12	12.9	93.1	(48.1-162.7)
Female	89	82.7	107.7	(86.5-132.5)	Female	12	11.6	103.1	(53.2-180.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	11	8.8	125.1	(62.4-223.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	35.1	105.5	(74.3-145.4)	Female	6	8.8	68.1	(24.9-148.2)
Female	32	33.4	95.8	(65.5-135.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.6	78.7	(28.7-171.3)
Male	8	6.4	124.9	(53.8-246.2)	Female	9	8.0	112.6	(51.4-213.7)
Female	2	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	104	92.0	113.0	(92.3-136.9)
Male	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.7	nc	(nc-nc)
Male	7	11.3	62.2	(24.9-128.2)	<u>Testis</u>				
Female	7	7.0	99.4	(39.8-204.9)	Male	2	3.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.9	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	6	10.4	57.6	(21.0-125.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	8.1	160.3	(85.3-274.1)	Female	19	18.7	101.6	(61.2-158.7)
Female	7	6.2	112.3	(45.0-231.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	370	327.9	112.8	(101.6-124.9)
Male	5	5.5	91.1	(29.3-212.5)	Female	346	300.5	115.1	(103.3-127.9)
Female	5	2.0	255.9	(82.5-597.1)					
<u>Lung and Bronchus</u>									
Male	57	47.3	120.6	(91.3-156.3)					
Female	67	44.3	151.3	(117.2-192.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.1	nc	(nc-nc)	Male	5	2.6	189.8	(61.2-442.9)
Female	1	0.9	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	14	14.5	96.2	(52.6-161.5)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	7	3.4	204.9	(82.1-422.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	15	13.6	110.4	(61.8-182.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.0	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Male	39	49.1	79.4	(56.5-108.6)
Female	0	0.1	nc	(nc-nc)	Female	44	43.7	100.6	(73.1-135.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	6.0	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	6	5.0	120.2	(43.9-261.7)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.9	nc	(nc-nc)	Male	15	5.5	275.2	(153.9-454.0)
Female	2	2.4	nc	(nc-nc)	Female	6	4.1	146.7	(53.6-319.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.5	(47.7-284.1)
Female	42	30.1	139.8	(100.7-188.9)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	11.7	119.2	(65.1-200.1)	Female	2	3.0	nc	(nc-nc)
Female	4	8.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	36	33.4	107.7	(75.4-149.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	4.2	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	5	4.5	112.0	(36.1-261.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.2	231.8	(74.7-541.0)	Female	8	6.6	120.5	(51.9-237.4)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	15.3	nc	(nc-nc)	Male	106	114.0	93.0	(76.1-112.5)
Female	21	12.2	172.1	(106.5-263.1)	Female	116	95.1	121.9	(100.8-146.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.5	111.8	(36.0-260.8)	Male	4	3.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	23	16.7	137.4	(87.0-206.1)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.5	92.0	(33.6-200.3)	Female	1	1.7	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	18.5	124.2	(78.7-186.4)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.3	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.5	nc	(nc-nc)	Female	5	3.8	133.3	(42.9-311.0)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	65	63.2	102.9	(79.4-131.1)
Male	1	1.2	nc	(nc-nc)	Female	50	55.3	90.4	(67.1-119.2)
Female	1	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.6	81.7	(32.7-168.2)					
Female	3	7.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	45.1	88.7	(63.4-120.8)	Male	31	26.2	118.3	(80.4-167.9)
Female	13	17.8	72.9	(38.8-124.6)	Female	32	21.8	146.5	(100.2-206.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.6	118.2	(53.9-224.4)	Male	1	6.9	nc	(nc-nc)
Female	10	6.8	146.3	(70.0-269.0)	Female	4	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	20	22.7	88.3	(53.9-136.4)
Female	151	159.9	94.4	(80.0-110.7)	Female	22	22.4	98.3	(61.6-148.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	6.3	126.7	(54.6-249.7)	Male	16	15.9	100.7	(57.5-163.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	75	61.8	121.4	(95.5-152.2)	Female	14	16.9	82.7	(45.1-138.7)
Female	71	64.6	109.9	(85.8-138.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	13.4	111.5	(62.4-184.0)
Male	14	11.4	122.8	(67.1-206.1)	Female	9	15.4	58.3	(26.6-110.8)
Female	3	3.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	151	164.9	91.6	(77.5-107.4)
Male	3	3.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.5	nc	(nc-nc)	Male	15	10.2	146.4	(81.9-241.5)
<u>Kidney & Renal Pelvis</u>					Female	6	7.1	84.6	(30.9-184.1)
Male	17	20.2	84.3	(49.1-135.0)	<u>Testis</u>				
Female	10	13.5	74.2	(35.5-136.4)	Male	4	4.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	7.0	nc	(nc-nc)	Male	5	6.1	81.3	(26.2-189.8)
Female	2	2.0	nc	(nc-nc)	Female	12	19.5	61.5	(31.8-107.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	14.1	141.8	(86.6-219.0)	Female	30	36.1	83.2	(56.1-118.8)
Female	11	11.9	92.1	(45.9-164.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	572	579.2	98.8	(90.8-107.2)
Male	3	9.8	nc	(nc-nc)	Female	556	577.8	96.2	(88.4-104.6)
Female	2	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	83	83.2	99.8	(79.5-123.7)					
Female	87	84.8	102.6	(82.2-126.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.5	77.9	(44.5-126.5)	Male	18	10.6	170.0	(100.7-268.8)
Female	7	7.1	98.2	(39.4-202.4)	Female	15	7.7	194.4	(108.7-320.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	177.4	(57.2-413.9)	Male	0	3.0	nc	(nc-nc)
Female	6	2.4	249.8	(91.2-543.8)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	9	9.4	96.0	(43.8-182.3)
Female	77	58.0	132.8	(104.8-166.0)	Female	10	8.6	116.4	(55.7-214.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	10	6.0	167.5	(80.2-308.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	27.0	77.7	(48.1-118.7)	Female	5	6.3	79.8	(25.7-186.3)
Female	22	26.2	84.0	(52.6-127.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.9	119.4	(47.8-246.1)
Male	6	4.7	127.5	(46.6-277.5)	Female	7	6.2	112.1	(44.9-231.0)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	93	65.7	141.6	(114.3-173.5)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	5	8.0	62.2	(20.0-145.0)	<u>Testis</u>				
Female	2	5.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	6.2	80.9	(26.1-188.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.9	118.1	(47.3-243.3)	Female	12	12.8	93.6	(48.3-163.5)
Female	6	4.6	130.9	(47.8-284.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	262	241.3	108.6	(95.8-122.5)
Male	2	3.9	nc	(nc-nc)	Female	233	217.3	107.2	(93.9-121.9)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	33	36.1	91.3	(62.8-128.2)					
Female	28	32.7	85.6	(56.9-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.8	70.6	(38.6-118.5)	Male	18	14.8	121.9	(72.2-192.6)
Female	5	6.9	72.5	(23.4-169.1)	Female	18	11.1	161.9	(95.9-255.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	12.4	137.5	(80.1-220.2)
Female	86	74.3	115.7	(92.6-142.9)	Female	12	9.4	127.6	(65.9-222.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	3.6	224.5	(96.7-442.4)	Male	7	9.3	75.5	(30.3-155.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	29.6	98.0	(65.6-140.7)	Female	12	7.7	155.4	(80.2-271.4)
Female	25	24.8	100.7	(65.2-148.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.3	159.8	(76.5-293.9)
Male	6	5.7	106.1	(38.7-230.8)	Female	4	5.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	81.2	88.7	(69.4-111.7)
Male	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.7	nc	(nc-nc)
Male	10	10.9	92.1	(44.1-169.5)	<u>Testis</u>				
Female	6	5.8	103.2	(37.7-224.6)	Male	5	5.2	97.0	(31.2-226.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.5	169.2	(61.8-368.3)	Male	7	4.5	155.2	(62.2-319.7)
Female	1	0.9	nc	(nc-nc)	Female	14	11.8	118.7	(64.8-199.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.4	94.0	(37.7-193.7)	Female	22	16.5	133.4	(83.5-201.9)
Female	4	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	290	291.3	99.5	(88.4-111.7)
Male	6	5.4	111.3	(40.6-242.3)	Female	285	253.8	112.3	(99.6-126.1)
Female	0	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	38.0	81.5	(55.4-115.7)					
Female	45	34.1	132.1	(96.4-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	133.2	(42.9-310.8)	Male	1	2.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	10	13.3	75.3	(36.1-138.6)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	5.5	128.4	(51.5-264.6)	Female	0	1.4	nc	(nc-nc)
Female	8	4.4	183.3	(78.9-361.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	15.0	66.8	(32.0-122.8)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	46	52.2	88.1	(64.5-117.5)
Male	0	1.0	nc	(nc-nc)	Female	43	44.2	97.3	(70.4-131.1)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	7.1	98.9	(39.6-203.8)					
Female	7	5.8	119.8	(48.0-246.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	85	86.0	98.8	(78.9-122.2)	Male	45	56.1	80.2	(58.5-107.3)
Female	23	33.7	68.2	(43.2-102.4)	Female	40	50.3	79.5	(56.8-108.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.1	88.5	(50.6-143.8)	Male	21	13.7	153.6	(95.0-234.8)
Female	13	16.0	81.1	(43.1-138.6)	Female	12	10.7	112.1	(57.9-195.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.8	nc	(nc-nc)	Male	39	48.0	81.2	(57.7-111.0)
Female	290	340.4	85.2	(75.7-95.6)	Female	51	44.9	113.7	(84.6-149.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	32	15.8	202.4	(138.4-285.7)	Male	35	34.4	101.6	(70.8-141.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	130	122.2	106.4	(88.9-126.3)	Female	40	35.6	112.2	(80.2-152.8)
Female	150	122.5	122.4	(103.6-143.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	25	26.3	95.2	(61.6-140.5)
Male	42	22.9	183.6	(132.3-248.2)	Female	34	29.0	117.4	(81.3-164.1)
Female	8	6.5	122.8	(52.9-242.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	268	331.0	81.0	(71.6-91.3)
Male	8	8.7	91.6	(39.4-180.4)	<u>Stomach</u>				
Female	4	7.5	nc	(nc-nc)	Male	27	19.9	135.4	(89.2-197.1)
<u>Kidney & Renal Pelvis</u>					Female	18	13.4	134.6	(79.7-212.7)
Male	45	42.1	106.8	(77.9-142.9)	<u>Testis</u>				
Female	34	27.4	124.3	(86.1-173.7)	Male	18	15.1	119.2	(70.6-188.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	17	14.2	119.4	(69.5-191.1)	Male	12	15.1	79.5	(41.0-138.9)
Female	4	4.1	nc	(nc-nc)	Female	58	51.0	113.7	(86.3-147.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	30.4	92.1	(61.2-133.0)	Female	63	75.9	83.0	(63.7-106.1)
Female	18	25.2	71.5	(42.3-113.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1183	1176.6	100.5	(94.9-106.4)
Male	24	20.6	116.7	(74.8-173.7)	Female	1213	1190.4	101.9	(96.2-107.8)
Female	6	7.4	81.4	(29.7-177.2)					
<u>Lung and Bronchus</u>									
Male	189	160.8	117.5	(101.4-135.5)					
Female	186	162.7	114.3	(98.5-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	15	12.6	118.7	(66.4-195.7)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	5.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	5	4.4	114.7	(37.0-267.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	8	13.5	59.2	(25.5-116.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.7	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.6	nc	(nc-nc)	Male	35	47.8	73.2	(51.0-101.8)
Female	0	0.2	nc	(nc-nc)	Female	53	43.2	122.6	(91.9-160.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	6.7	74.7	(24.1-174.2)	<u>All Sites / Types</u>				
Female	15	6.1	244.0	(136.5-402.5)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	53.8	93.0	(69.0-122.6)	Male	61	34.4	177.3	(135.6-227.8)
Female	21	22.4	93.7	(58.0-143.2)	Female	57	33.4	170.6	(129.2-221.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	10.3	125.9	(67.0-215.3)	Male	5	8.5	58.9	(19.0-137.6)
Female	9	9.9	91.3	(41.7-173.3)	Female	4	7.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	41	29.3	139.9	(100.4-189.8)
Female	229	218.7	104.7	(91.6-119.2)	Female	37	29.6	124.9	(88.0-172.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	10.3	67.8	(27.2-139.7)	Male	16	20.8	77.1	(44.0-125.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	64	75.9	84.3	(64.9-107.7)	Female	30	23.2	129.2	(87.2-184.5)
Female	63	83.7	75.3	(57.8-96.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	16.3	98.4	(56.2-159.8)
Male	9	14.0	64.4	(29.4-122.2)	Female	18	19.5	92.1	(54.6-145.6)
Female	4	4.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	224	200.5	111.7	(97.6-127.3)
Male	7	5.2	133.4	(53.4-274.8)	<u>Stomach</u>				
Female	5	5.0	99.9	(32.2-233.1)	Male	6	12.5	48.1	(17.5-104.6)
<u>Kidney & Renal Pelvis</u>					Female	7	9.3	75.2	(30.1-155.0)
Male	29	25.4	114.3	(76.5-164.1)	<u>Testis</u>				
Female	18	17.5	102.7	(60.8-162.2)	Male	16	9.7	165.7	(94.7-269.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	8.7	69.1	(25.2-150.5)	Male	21	9.1	231.1	(143.0-353.3)
Female	1	2.6	nc	(nc-nc)	Female	56	33.3	168.3	(127.1-218.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	18.1	144.0	(94.0-210.9)	Female	53	48.4	109.6	(82.1-143.4)
Female	21	16.2	130.0	(80.4-198.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	725	719.6	100.7	(93.5-108.4)
Male	10	12.5	79.8	(38.2-146.7)	Female	799	777.8	102.7	(95.7-110.1)
Female	4	4.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	66	98.6	66.9	(51.8-85.1)					
Female	86	104.6	82.2	(65.8-101.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	8	8.3	96.9	(41.7-191.0)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	9.3	53.9	(17.4-125.9)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	32.3	89.9	(60.2-129.1)
Male	1	0.6	nc	(nc-nc)	Female	20	27.8	71.9	(43.9-111.0)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.5	nc	(nc-nc)					
Female	4	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	25.7	81.8	(50.6-125.1)	Male	19	16.5	115.1	(69.3-179.8)
Female	6	9.1	65.7	(24.0-142.9)	Female	15	13.1	114.7	(64.1-189.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.0	100.1	(32.2-233.5)	Male	5	4.1	121.4	(39.1-283.4)
Female	4	4.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	13.9	93.5	(49.8-160.0)
Female	100	95.0	105.2	(85.6-128.0)	Female	11	11.9	92.5	(46.1-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.1	122.0	(39.3-284.7)	Male	6	10.5	57.1	(20.9-124.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	36.5	65.8	(42.1-97.9)	Female	4	9.8	nc	(nc-nc)
Female	35	31.6	110.6	(77.0-153.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.0	100.4	(43.2-197.8)
Male	7	7.1	99.0	(39.6-203.9)	Female	9	7.7	117.5	(53.6-223.0)
Female	3	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	110	107.6	102.3	(84.1-123.3)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.6	nc	(nc-nc)	Male	6	5.8	103.5	(37.8-225.2)
<u>Kidney & Renal Pelvis</u>					Female	2	3.3	nc	(nc-nc)
Male	8	12.8	62.4	(26.9-123.0)	<u>Testis</u>				
Female	6	7.6	78.9	(28.8-171.8)	Male	4	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.5	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	15	13.1	114.9	(64.3-189.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	8.4	166.1	(90.7-278.7)	Female	24	22.2	108.2	(69.3-161.0)
Female	6	6.2	96.1	(35.1-209.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	341	358.3	95.2	(85.3-105.8)
Male	6	6.3	95.6	(34.9-208.0)	Female	346	322.9	107.1	(96.1-119.0)
Female	1	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	49.7	102.6	(76.4-134.9)					
Female	50	46.2	108.3	(80.3-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	75.1	69.2	(51.7-90.8)	Male	42	52.0	80.7	(58.2-109.1)
Female	23	30.3	75.8	(48.0-113.7)	Female	41	50.2	81.6	(58.6-110.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	16.6	78.2	(41.6-133.8)	Male	11	12.0	91.6	(45.7-164.0)
Female	8	14.8	54.0	(23.3-106.5)	Female	9	9.6	93.3	(42.6-177.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.4	nc	(nc-nc)	Male	43	44.1	97.5	(70.5-131.3)
Female	300	312.7	95.9	(85.4-107.4)	Female	36	41.3	87.1	(61.0-120.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	16.0	nc	(nc-nc)	Male	27	30.5	88.4	(58.3-128.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	97	107.4	90.3	(73.3-110.2)	Female	33	33.1	99.6	(68.5-139.9)
Female	100	110.7	90.3	(73.5-109.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	22.8	83.3	(50.1-130.1)
Male	9	19.9	45.3	(20.7-86.0)	Female	22	26.0	84.5	(52.9-128.0)
Female	6	5.8	102.7	(37.5-223.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	265	283.7	93.4	(82.5-105.3)
Male	9	10.8	83.1	(37.9-157.8)	<u>Stomach</u>				
Female	3	9.0	nc	(nc-nc)	Male	22	17.6	125.0	(78.3-189.2)
<u>Kidney & Renal Pelvis</u>					Female	18	12.1	148.6	(88.0-234.9)
Male	23	37.1	62.1	(39.3-93.1)	<u>Testis</u>				
Female	18	24.9	72.3	(42.9-114.3)	Male	16	21.1	76.0	(43.4-123.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	12.3	81.1	(38.8-149.2)	Male	20	15.4	130.0	(79.4-200.9)
Female	3	3.7	nc	(nc-nc)	Female	54	53.3	101.3	(76.1-132.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	27.5	72.6	(44.3-112.2)	Female	66	69.4	95.1	(73.5-120.9)
Female	19	22.6	84.1	(50.6-131.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	901	1045.5	86.2	(80.6-92.0)
Male	27	18.1	149.1	(98.3-217.0)	Female	958	1099.6	87.1	(81.7-92.8)
Female	14	6.7	209.4	(114.4-351.4)					
<u>Lung and Bronchus</u>									
Male	109	139.5	78.2	(64.2-94.3)					
Female	98	146.1	67.1	(54.4-81.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.9	85.4	(54.1-128.1)	Male	15	16.1	93.3	(52.2-153.9)
Female	16	10.8	148.6	(84.9-241.3)	Female	8	13.5	59.4	(25.6-117.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	9	13.9	65.0	(29.6-123.3)
Female	90	97.0	92.8	(74.6-114.1)	Female	15	13.6	110.1	(61.6-181.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	6	9.8	61.3	(22.4-133.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	37.4	115.1	(83.3-155.0)	Female	3	10.3	nc	(nc-nc)
Female	41	40.0	102.6	(73.6-139.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.1	136.4	(68.0-244.1)
Male	8	6.8	117.1	(50.4-230.7)	Female	9	9.4	95.6	(43.6-181.5)
Female	0	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	103	98.3	104.8	(85.5-127.1)
Male	4	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.6	nc	(nc-nc)	Male	7	6.2	112.8	(45.2-232.5)
<u>Kidney & Renal Pelvis</u>					Female	3	4.5	nc	(nc-nc)
Male	12	12.2	98.2	(50.7-171.5)	<u>Testis</u>				
Female	8	8.1	99.1	(42.7-195.2)	Male	2	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	21	12.2	172.5	(106.7-263.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.6	81.3	(32.6-167.5)	Female	18	21.4	83.9	(49.7-132.7)
Female	5	7.4	67.5	(21.7-157.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	334	348.6	95.8	(85.8-106.7)
Male	4	6.0	nc	(nc-nc)	Female	332	351.0	94.6	(84.7-105.3)
Female	3	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	49.2	87.5	(63.3-117.8)					
Female	47	49.9	94.1	(69.1-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;